HIGHLIGHTS
- who: Mercedes Porosnicu and collaborators from the University General Hospital Attikon, Greece have published the article: Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status, in the Journal: (JOURNAL)
- what: This study investigates the possibility of improved treatment response through patient smoking status-based erlotinib dose optimization and through early in-treatment FDG PET evaluation to differentiate responders from non-responders. The study aimed to investigate the clinical and tissue effect and tolerance of a short course of erlotinib administered . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.